RxDoctor Payments Data

Yonwook Kim, MD

Glaucoma Specialist · Fairfax, VANPI 1821524331

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by Biotissue Holdings Inc. at 49.1% of the total. Reporting peaked in 2022 at $2,345 and has fallen 80.4% since, to $461 in 2025.

$4,144in general payments, 2019–2025

Across 40 payments — averaging $103.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$2K
  • AbbVie$624
  • Sight Sciences, Inc.$551
  • Alcon$541
  • Tarsus Pharmaceuticals, Inc.$176
  • Glaukos Corporation$90
  • plus $129 from 6 others

What the payments were for

  • Travel & lodging$1,76142%
  • Food & beverage$2,38358%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$333,706
Medicare patients
901
Services billed
2,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate65$29,962
LumiganBimatoprost21$14,858
RocklatanNetarsudil Mesylat/Latanoprost23$11,018
CombiganBrimonidine Tartrate/Timolol12$6,180
Prednisolone Acetate144$5,197
Latanoprost468$4,709
Brimonidine Tartrate334$4,651
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat246$4,295
VyzultaLatanoprostene Bunod14$3,849
SimbrinzaBrinzolamide/Brimonidine Tart11$3,496
Brinzolamide13$3,183
Timolol Maleate200$2,783
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,211
Dorzolamide Hcl84$1,672
Ofloxacin34$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$624$21,03833 claims
Bausch & Lomb Americas Inc.Vyzulta$25$3,84914 claims
AlconSimbrinza$541$3,49611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →